At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PTIX Protagenic Therapeutics Inc
Market Closed 12-12 16:00:00 EST
1.65
+0.07
+4.43%
盘后1.61
-0.04-2.42%
19:59 EST
High1.68Low1.55Vol113.95K
Open1.56D1 Closing1.58Amplitude7.99%
Mkt Cap3.19MTradable Cap3.16MTotal Shares1.93M
T/O184.51KT/O Rate5.95%Tradable Shares1.91M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Protagenic Therapeutics Reports Positive Phase 1 Results for PT00114 in Stress-Related Psychiatric Disorders
Reuters  ·  12-09
Protagenic Therapeutics Reports Positive Phase 1 Results for PT00114 in Stress-Related Psychiatric Disorders
Protagenic Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting
Reuters  ·  12-06
Protagenic Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting
Sector Update: Health Care Stocks Mixed Premarket Friday
MT Newswires Live  ·  11-28
Sector Update: Health Care Stocks Mixed Premarket Friday
Protagenic Therapeutics Faces Nasdaq Delisting Due to Compliance Issues
MT Newswires Live  ·  11-28
Protagenic Therapeutics Faces Nasdaq Delisting Due to Compliance Issues
Protagenic Therapeutics Delays Quarterly Financial Report
Reuters  ·  11-27
Protagenic Therapeutics Delays Quarterly Financial Report
Protagenic Therapeutics Delays Quarterly Report Filing
Reuters  ·  11-15
Protagenic Therapeutics Delays Quarterly Report Filing
Protagenic Therapeutics Completes Dosing in Phase 1 Study of Lead Compound PT00114
Reuters  ·  11-13
Protagenic Therapeutics Completes Dosing in Phase 1 Study of Lead Compound PT00114
Jennifer Chao Resigns from Protagenic Therapeutics Board
Reuters  ·  11-06
Jennifer Chao Resigns from Protagenic Therapeutics Board
Protagenic Therapeutics Inc: Files Complaint to Rescind Share Exchange Agreement by Which Co Acquired Phytanix Bio - SEC Filing
THOMSON REUTERS  ·  11-01
Protagenic Therapeutics Inc: Files Complaint to Rescind Share Exchange Agreement by Which Co Acquired Phytanix Bio - SEC Filing
Protagenic Therapeutics: May Offer and Sell Shares of Common Stock of up to $1.75 Mln - SEC Filing
THOMSON REUTERS  ·  10-25
Protagenic Therapeutics: May Offer and Sell Shares of Common Stock of up to $1.75 Mln - SEC Filing
Protagenic Therapeutics Files Initial Beneficial Ownership Statement; Ex-CEO and Director Barrett Evans Named as 10% Owner
Reuters  ·  10-25
Protagenic Therapeutics Files Initial Beneficial Ownership Statement; Ex-CEO and Director Barrett Evans Named as 10% Owner
Top Midday Gainers
MT Newswires Live  ·  08-22
Top Midday Gainers
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026
Reuters  ·  08-21
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026
Protagenic Therapeutics Inc. Delays Q2 Financial Report Due to Transition to Virtual Operating Model
Reuters  ·  08-15
Protagenic Therapeutics Inc. Delays Q2 Financial Report Due to Transition to Virtual Operating Model
BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing
Reuters  ·  08-14
BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing
Protagenic Therapeutics to Pause Trials, Remove CEO in Restructuring
Dow Jones  ·  08-14
Protagenic Therapeutics to Pause Trials, Remove CEO in Restructuring
Protagenic Therapeutics Inc: Has Temporarily Suspended Expenditures Related to Preclinical Programs
THOMSON REUTERS  ·  08-14
Protagenic Therapeutics Inc: Has Temporarily Suspended Expenditures Related to Preclinical Programs
Protagenic Therapeutics : Terminated Employment of Barrett Evans as CEO and President and Colin Stott as Chief Operating Officer
THOMSON REUTERS  ·  08-14
Protagenic Therapeutics : Terminated Employment of Barrett Evans as CEO and President and Colin Stott as Chief Operating Officer
Protagenic Therapeutics:All Preclinical Programs Originated With Former Phytanix Bio (Phyx-001,Phyx-002,Phyx-003,Phyx-004, Phyx-005) Have Been Paused
THOMSON REUTERS  ·  08-14
Protagenic Therapeutics:All Preclinical Programs Originated With Former Phytanix Bio (Phyx-001,Phyx-002,Phyx-003,Phyx-004, Phyx-005) Have Been Paused
Protagenic Therapeutics Inc: Initiated Process to Evaluate Strategic Alternatives for Those Programs, Including Partnerships and/or Out-Licensing
THOMSON REUTERS  ·  08-14
Protagenic Therapeutics Inc: Initiated Process to Evaluate Strategic Alternatives for Those Programs, Including Partnerships and/or Out-Licensing

Introduction

Company Name.
Protagenic Therapeutics Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Issue price:
--